Stockreport

Cabaletta Bio Announces 2026 Strategic Priorities

Cabaletta Bio, Inc.  (CABA) 
PDF Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single w [Read more]